Septerna (SEPN) shares were down sharply premarket Tuesday after the company said it has discontinued a phase 1 clinical trial of SEP-786 for the potential treatment of hypoparathyroidism in healthy volunteers.
The company said the decision follows two unanticipated severe events of elevated unconjugated bilirubin in a portion of the trial, though there were no occurrences of liver injury, cholestasis, or hemolysis among participants and no serious adverse events.
The company said its cash, cash equivalents, and marketable securities totaled $137.5 million as of Sept. 30. Together with $302.6 million in net proceeds from its October IPO, Septerna said it expects its current cash position to support operations into at least H2 2027.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。